Tercica, a biotechnology company, develops and commercializes therapeutics for the treatment of endocrine and metabolic diseases.
Business Model:
Revenue: $0
Employees: 501-1,000
Address:
City: Brisbane
State: California
Zip:
Country: United States
Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA. The company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A.
Contact Phone:
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
3/17/2004
Ticker Symbol:
TRCA
IPO Price:
$9/share
Amount Raised:
$50M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 7/2003 | Series B | 5 | $44M |
Care Capital MedImmune Ventures MPM Capital Prospect Venture Partners Rho Ventures Care Capital MedImmune Ventures MPM Capital Prospect Venture Partners Rho Ventures |
3/2002 | Series A | 1 | $21.5M |
Genentech Genentech Genentech Genentech |
7/2007 | Post-IPO Equity | 1 | $8M |
GenenFUND GenenFUND |
10/2005 | Post-IPO Equity | 1 | $75M |
Kingsbridge Capital Kingsbridge Capital |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|